As the accompanying FGFR2 amplification did not affect the chemotherapy response in advanced gastric cancer in present and previous studies [31, 32], it could be hypothesized that the FGFR2 inhibitor would be more effective when combined with cytotoxic agents. This evidence concerns the gene FGFR2 and gastric cancer.